Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals, Inc. (AMRX) Form 144 indicates a proposed sale of 84,036 common shares through Charles Schwab, with an aggregate market value of $818,930.82. The filing lists approximately 314,079,309 shares outstanding and an approximate sale date of 08/22/2025 on NASDAQ. The securities were acquired on 07/05/2018 as executive compensation. The filing also discloses two recent sales by the named person: 71,694 shares sold on 08/14/2025 for $666,037.26 and 50,000 shares sold on 08/12/2025 for $452,030.89. The signer represents they are not aware of any undisclosed material adverse information about the issuer.
Amneal Pharmaceuticals (AMRX) reported a Form 144 notice showing proposed sales by an affiliate. The filer intends to sell 175,000 Class A shares with an aggregate market value of $1,637,900, against approximately 314.08 million shares outstanding, with an approximate sale date of 08/20/2025 on NASDAQ. The filing records the shares were acquired as stock options on 05/07/2018 from Amneal Pharmaceuticals. The form also discloses prior sales in the past three months totaling 137,680 Class A shares for gross proceeds of $1,272,163 (sales on 08/12/2025 and 08/20/2025). The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for Amneal Pharmaceuticals, Inc. (AMRX) reports a proposed sale of 104,244 common shares with an aggregate market value of $969,469, to be effected approximately on 08/20/2025 on NASDAQ through Charles Schwab.
The filing shows those 104,244 shares were acquired as restricted stock awards on multiple dates between 02/27/2022 and 03/03/2024 and paid as equity compensation. The issuer's total outstanding shares are reported as 314,079,309. The filing also discloses a prior sale by an identified seller, Andrew Boyer, of 33,436 shares on 08/12/2025 for $302,694. The signer certifies no undisclosed material adverse information and includes the standard Rule 144 representations.
Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), reported the sale of 71,694 shares of Class A common stock on 08/14/2025 at a weighted-average price of $9.29 per share, with individual trade prices ranging from $9.16 to $9.41. After the reported dispositions, the reporting person beneficially owned 267,235 shares, held directly. The Form 4 was filed indicating the transaction type as a sale and includes an explanatory footnote that the reported price is a weighted average from multiple trades. The form is signed by an attorney-in-fact on 08/15/2025.
Amneal Pharmaceuticals (AMRX) insider selling reported on Form 4. Executive Vice President & CFO Tasos Konidaris disposed of a total of 499,730 shares across three sale dates: 161,365 shares on 08/13/2025 at a weighted average price of $9.22, 119,206 shares on 08/14/2025 at $9.30, and 219,159 shares on 08/15/2025 at $9.43. After these transactions the reporting person beneficially owned 122,152 shares.
The filing shows the sales were executed in multiple transactions with price ranges disclosed in footnotes and signed by an attorney-in-fact. No derivative transactions, grants, or acquisitions are reported on this form and no explanatory statements beyond weighted-average price ranges were provided.
Insider sale notice for Amneal Pharmaceuticals (AMRX). The Form 144 reports a proposed sale of 219,159 common shares with an aggregate market value of $2,057,903.01 to be sold on or about 08/15/2025 on NASDAQ. The filing shows the securities were acquired through RSU vesting on three dates in March 2024 totaling 219,159 shares. The document also discloses recent completed sales by Anastasios Konidaris: 161,635 shares sold on 08/13/2025 for gross proceeds of $1,489,993.93 and 119,206 shares sold on 08/14/2025 for gross proceeds of $1,108,993.36. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Amneal Pharmaceuticals (AMRX) Form 144: This notice reports a proposed sale of 71,694 Class A shares (aggregate market value $663,065) to be sold on or about 08/14/2025 on NASDAQ. The shares were acquired through equity compensation from Amneal Pharmaceuticals on 02/27/2024 (16,950 shares), 03/01/2024 (13,776 shares) and 03/03/2024 (40,968 shares), matching the 71,694 units listed. The filing lists the total Class A shares outstanding as 314,079,309. The notice also discloses sales by the same person in the past three months: 50,000 shares sold on 08/12/2025 for $453,000 and 49,140 shares sold on 05/16/2025 for $370,542. By signing, the seller represents they possess no undisclosed material information about the issuer.
Amneal Pharmaceuticals, Inc. (AMRX) Form 4 shows that reporting person Shah Nikita, listed as Executive Vice President and filing as an officer, sold 50,000 shares of Class A common stock on 08/12/2025. The filing reports a weighted average price of $9.04 and discloses the sales occurred in multiple transactions at prices ranging from $9.03 to $9.07. The sale is reported as a direct disposition.
The filing states the reporting person now beneficially owns 338,929 shares directly. The Form 4 was signed by attorney-in-fact Denis Butkovic on 08/13/2025. No derivative securities are reported on this Form 4.
Amneal Pharmaceuticals insider sale: Jason B. Daly, EVP and Chief Legal Officer, sold 22,000 shares of Class A common stock at a weighted average price of $9.05 per share on 08/12/2025. After the reported sale, Daly directly holds 10,606 shares. The filing notes the sale was executed in multiple transactions with prices ranging from $9.01 to $9.13 and that full per-trade details will be provided to the company or the SEC on request. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.
Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported the sale of Class A common stock on 08/12/2025. The filing shows 33,436 shares were disposed in one or more transactions at a weighted average price of approximately $9.05 per share, with individual trade prices ranging from $9.05 to $9.07.
After these transactions, Boyer directly beneficially owns 256,670 shares. The Form 4 discloses no derivative transactions and includes a footnote stating the sales were executed in multiple transactions and that the reporting person will provide detailed per-price allocation upon request.